Advertisement
Advertisement
VKTX
Viking Therapeutics, Inc
34.26
USDSponsored
-1.72
-4.79%
Aug 20, 13:00 UTC -4
Open
VKTX Earnings Reports
Positive Surprise Ratio
VKTX beat 23 of 43 last estimates.
53%
Next Report
Date of Next Report
Oct 20, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$1.13
Implied change from Q2 26 (Revenue/ EPS)
--
/+2.73%
Implied change from Q3 25 (Revenue/ EPS)
--
/+39.51%
Viking Therapeutics, Inc earnings per share and revenue
On Jul 29, 2026, VKTX reported earnings of -1.10 USD per share (EPS) for Q2 26, beating the estimate of -1.27 USD, resulting in a 13.52% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.96% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -1.13 USD, with revenue projected to reach -- USD, implying an increase of 2.73% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.18
Actual
-$1.44
Surprise
-21.23%
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
Biofrontera Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.05
Surprise
+53.31%
FAQ
What were Viking Therapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Viking Therapeutics, Inc reported EPS of -$1.10, beating estimates by 13.52%, and revenue of $0.00, 0% as expectations.
How did the market react to Viking Therapeutics, Inc's Q2 2026 earnings?
The stock price moved down -0.96%, changed from $33.43 before the earnings release to $33.11 the day after.
When is Viking Therapeutics, Inc expected to report next?
The next earning report is scheduled for Oct 20, 2026.
What are the forecasts for Viking Therapeutics, Inc's next earnings report?
Based on 10
analysts, Viking Therapeutics, Inc is expected to report EPS of -$1.13 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement